id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-002500-9p2n8tjx	Lambe, Teresa	A review of Phase I trials of Ebola virus vaccines: what can we learn from the race to develop novel vaccines?	2017-05-26		.txt	text/plain	7327	288	38	The other vaccine modality being assessed as an Ebola vaccine candidate is the recombinant vesicular stomatitis virus encoding EBOV glycoprotein (rVSV-ZEBOV), which is an attenuated replication-competent viral vector. In the absence of any gold standard for measuring humoral immunity against Ebola virus, a wide variety of assays were used to evaluate antibody responses to vaccines during the recent EVD outbreak. Many of the other binding assays used in these Phase I trials correlate strongly and, in particular, it is useful that the standardized glycoprotein ELISA and pseudotyped lentivirus assays each correlate strongly with neutralizing titres against live Ebola virus as these assays avoid the need to work at high containment levels, but may be used to indicate the presence of antibodies with neutralizing activity. In a pre-clinical NHP model, IgG responses after immunization with AdHu5-based Ebola virus vaccines were measured using an ELISA against GP, where 100% protection against a lethal challenge was predicted by titres of 3700 or greater, while a titre of around 2000 predicted 85% survival.	./cache/cord-002500-9p2n8tjx.txt	./txt/cord-002500-9p2n8tjx.txt